Needham & Company Remains Sidelined on Marvell Technology (MRVL) Following 4Q

Marvell Technology (MRVL) Attempts Red-to Green Reversal Following Additional Purchase of 17,500 Mar 16 Calls

March 6, 2017 3:53 PM EST

An additional 17,500 Mar 16 Calls were purchased on the offer at $0.30, shortly after 2:30pm EST. Earlier in the session, Susquehanna option strategist Alison Edwards noted a... More

Susquehanna Sees Bullish Options Activity in Marvell Technology (MRVL) Ahead of Analyst Day; Earlier Today Citi Raised PT

March 6, 2017 2:02 PM EST

Susquehanna option strategist Alison Edwards notes bullish options activity in Marvell Technology Group (NASDAQ: MRVL), as an investor purchased 5000 March 16 Calls today ahead of this week's analyst meeting.

Earlier today, Citi analyst... More

Cowen Reiterates Outperform Rating and $20 PT on Marvell (MRVL) Following 4Q EPS Beat

March 3, 2017 6:09 AM EST

Cowen analyst Timothy Arcuri reiterates Outperform rating and $20 price target Marvell (NASDAQ: MRVL), as the company reported solid fourth quarter results and guidance, with EPS above the Street.

Arcuri comments, "With another solid Q/guide, next week's Analyst Day should represent a... More

Marvell (MRVL) PT Raised to $17 at Morgan Stanley

March 3, 2017 3:46 AM EST

Morgan Stanley raised its price target on Marvell (NASDAQ: MRVL) to $17.00 (from $14.00) while maintaining a Equalweight rating.

Analyst Joseph Moore likes the progress MRVL has made in turning the company around but remains skeptical that growth will return for the... More

After-Hours Stock Movers 03/02: (HABT) (VTTI) (GWRE) Higher; (SCYX) (IMMR) (KPTI) Lower (more...)

March 2, 2017 6:06 PM EST

Today's After-Hours Movers:

SCYNEXIS, Inc. (Nasdaq: SCYX) 30% LOWER; announced that the United States Food and Drug Administration (FDA) has informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data of the IV formulation of SCY-078. Ongoing and future trials using the oral formulation of SCY-078 are unaffected by this regulatory action. A meeting with the FDA to discuss these data and to agree on... More

Marvell Technology (MRVL) Tops Q4 EPS by 3c; Issues Solid Outlook

March 2, 2017 4:06 PM EST

Marvell Technology (NASDAQ: MRVL) reported Q4 EPS of $0.22, $0.03 better than the analyst estimate of $0.19. Revenue for the quarter came in at $571.4 million versus the consensus estimate of $567.64 million.

Q4 Revenue: $571 MillionQ4 GAAP gross margin of 57.3%; Non-GAAP gross margin of 57.6%Q4 GAAP... More

Marvell Technology (MRVL) March weekly and March 16 calls are active into Q4

March 2, 2017 3:19 PM EST

Marvell Technology (NASDAQ: MRVL) March weekly and March 16 calls are active on total call volume of 16K contracts (3K puts) into the expected release of Q4 results on March 2. March weekly call option implied volatility is at 123, March is at 43, April is at 34; compared to its 52-week range of 27 to 57.

... More

Goldman Sachs Upgrades Marvell (MRVL) to Neutral

March 1, 2017 3:29 AM EST

Goldman Sachs upgraded Marvell (NASDAQ: MRVL) from Conviction Sell to Neutral with a price target of $16.00 (from $12.00).

Analyst Mark Delaney comments "We believe that HDD demand trends have improved since Marvell last issued guidance (11/17/16). GS hardware analyst Simona Jankowski raised her 2017 PC... More